Get an Lp(a) test — and 3 other things you must do now for heart health

Rising deaths from heart disease among younger adults prompt preventive cardiologists to recommend specific actions, foremost getting an Lp(a) test. The opinion urges earlier cardiovascular risk assessment and adoption of updated prevention measures (lifestyle and medical) to address the projected increase in heart disease incidence.

Analysis

A ramp in preventative screening creates a clear demand shock for centralized and high-throughput diagnostics: national labs and assay platforms will see outsized marginal revenue from incremental lipid and Lp(a) assays because fixed-cost lab infrastructure magnifies margin on volume. Expect an initial 3–12 month uptick concentrated in wellness panels and cardiology referrals, with durable secular growth only if payors create a reproducible reimbursement pathway.

Pharma winners are bifurcated: incumbents with already-approved, reimbursed lipid-lowering therapies (PCSK9/inclisiran franchises) capture immediate off-label/adjunct spend as clinicians intensify risk reduction, while pure-play Lp(a) developers carry binary clinical/outcome risk that could move valuations by multiples when phase 3 event data land (12–36 months). Reagent and consumables suppliers (highly concentrated oligopoly) are second-order beneficiaries — modest volume increases translate into outsized margin flow-through for firms with integrated manufacturing.

Key gating items are non-clinical: CPT/coding updates, national coverage decisions, and EMR order-set integration — each can flip a localized pilot into a national program within 6–18 months or, if delayed, cap adoption for multiple years. Tail risks include a negative outcome from a pivotal Lp(a) event trial, a high-cost-effectiveness hurdle imposed by payors, or clinician inertia that keeps testing confined to specialists rather than primary care.

Contrarian view: the market may be overstating near-term upside to diagnostics players because testing demand without a clear, reimbursed therapeutic pathway creates low-acuity volumes that are easy to price-shift or de-prioritize; conversely, integrated health systems and value-based payors who can monetize avoided events are the symmetry winners and under-owned by public markets today.

Key Decisions for Investors

• Long LabCorp (LH) or Quest Diagnostics (DGX), 6–12 month horizon: buy shares or buy-call spread (6–9 month) to play near-term testing volume + coding catalysts. Risk: reimbursement stalls or lab mix-shift; reward: 15–30% upside if national screening pilots expand.
• Long Novartis (NVS) and Amgen (AMGN), 12–24 month horizon: overweight leaders in RNA/PCSK9-class lipid lowering to capture increased adjunct therapy demand. Use a paired approach (equal notional) to reduce broader pharma beta; risk: pricing pressure and guideline inertia, reward: sustained share growth and cash flow expansion if prevention protocols are updated.
• Tactical options: buy DGX 3–6 month calls ahead of anticipated CPT/coverage announcements (if available) for asymmetric upside vs premium paid. Limit position size to defined premium at risk — downside limited to premium, upside amplified by volume surprise.
• Underweight/avoid standalone small-cap Lp(a) developers lacking near-term outcome data; consider pair: short speculative Lp(a) developer vs long established diagnostics or integrated health system (e.g., large value-based care operator) to hedge binary clinical-readout risk within 12–36 months.